AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Influenza T cell epitope induces influenza protection in mice.
2003 AUG 6 - (NewsRx.com & NewsRx.net) -- The immunodominant influenza matrix T cell epitope recognized in humans induced influenza protection in HLA-A2/K-b transgenic mice.
According to recent research from France, "The protective efficacy of the influenza matrix protein epitope 58-66 (called M1), recognized in the context of human HLA-A2 molecules. was evaluated in a HLA-A2/K-b transgenic mouse model of lethal influenza infection."
"Repeated subcutaneous immunizations with M1 increased the percentage of survival," reported Helene Plotnicky and collaborators at the Centre d'Immunologie Pierre Fabre. "This effect was mediated by T cells since protection was abolished following in vivo depletion of all T lymphocytes, CD8+, or CD4+ T cells."
The researchers found, "The survival correlated with the detection of memory CD8+ splenocytes able to proliferate in vitro upon stimulation with M1 and to bind M1-loaded HLA-A2 dimers, as well as with M1-specific T cells in the lungs, which were directly cytotoxic to influenza-infected cells following influenza challenge."
"These results demonstrated ...
- Pierre Fabre Donates the Majority Equity Interest in his Company to his...
- Press release article from: PR Newswire September 5, 2008 700+ words
...commitment made in 2005 to his employees, Mr. Pierre Fabre asked the Pierre Fabre Foundation's board of directors to accept the donation of 100% of the equity of Pierre Fabre Participation, a holding company with a 60...
- Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development...
- Press release article from: PR Newswire December 22, 2008 700+ words
...Forest Laboratories, Inc. and Pierre Fabre Medicament today announced that they...inhibitor that is being developed by Pierre Fabre for the treatment of depression and...Forest will make an upfront payment to Pierre Fabre of $75 million and will pay future...
- Javlor(R) (Vinflunine) From Pierre Fabre Medicament Enters in Phase III...
- Press release article from: PR Newswire September 10, 2003 700+ words
...France, Sept. 10 /PRNewswire/ -- Pierre Fabre Medicament is announcing today the launch...says Patrick Hurteloup, director of Pierre Fabre Oncologie(1). "They should allow...encouraging results". Originated at the Pierre Fabre Research Center, Javlor(R) (vinflunine...
- Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat...
- Press release article from: PR Newswire May 6, 2009 700+ words
...France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce...strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety...
- Novacea and Pierre Fabre Medicament Enter Into Partnership for the Development...
- Press release article from: PR Newswire July 25, 2005 700+ words
...PRNewswire/ -- Novacea Inc. and Pierre Fabre Medicament S.A. announced today...treatment of various tumor types. Pierre Fabre has licensed the U.S. and Canadian rights to Novacea, while Pierre Fabre will continue to develop and commercialize...
- Pierre Fabre Dermo Cosmetique USA to Acquire Genesis Pharmaceutical, Inc.
- Press release article from: PR Newswire October 2, 2002 700+ words
...France and PARSIPPANY, N.J. -- Pierre Fabre Group, through a newly formed subsidiary, Pierre Fabre Dermo Cosmetique USA, announced today...operate as a wholly owned subsidiary of Pierre Fabre Dermo Cosmetique USA, and will continue...
- Cypress Bioscience Revises Milnacipran License With Pierre Fabre Medicament to...
- Press release article from: PR Newswire June 9, 2003 700+ words
...its Milnacipran license agreement with Pierre Fabre Medicament, SA, Paris, France. The...indication in the United States and Canada. Pierre Fabre Medicament will continue to have the...active pharmaceutical ingredient from Pierre Fabre and makes certain other changes to the...
- Lilly and bioMerieux-Pierre Fabre To Collaborate on ACAT Inhibitor for...
- Press release article from: Business Wire May 3, 2001 700+ words
...Company (NYSE:LLY) and bioMerieux-Pierre Fabre announced today they have signed a letter...inhibitor discovered at bioMerieux-Pierre Fabre's research center in Castres, France...atherosclerotic plaque, Lilly and bioMerieux-Pierre Fabre anticipate eflucimibe could represent...
